NewAmsterdam Pharma Company N.V. (NAMS)
USD 25.89
(-2.71%)
USD 25.89
(-2.71%)
| Breakdown | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Operating Cash Flow | -128.32 Million | 7.97 Million | -25.16 Million | -5.97 Million |
| Net Income | -160.78 Million | -78.05 Million | -28.59 Million | -5.74 Million |
| Depreciation & Amortization | 44.52 Thousand | 72 Thousand | 14 Thousand | 1000.00 |
| Deferred income taxes | 4.74 Million | - | -1.44 Million | - |
| Stock-based compensation | 22.32 Million | 4.11 Million | 1.24 Million | - |
| Change in working capital | 5.33 Million | 11.46 Million | 3.82 Million | -528 Thousand |
| Other non-cash items | 5452.19 | 70.56 Million | -7000.00 | 306 Thousand |
| Investing Cash Flow | -21.8 Thousand | 715 Thousand | -20 Thousand | -13 Thousand |
| Investments in PPE | -21.8 Thousand | -13 Thousand | -20 Thousand | -13 Thousand |
| Acquisitions | - | - | - | - |
| Investment purchases | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - |
| Other Investing Activities | -21.8 Thousand | 728 Thousand | - | -112.78 Million |
| Financing Cash Flow | 8.09 Million | 375.17 Million | 68.99 Million | 11.32 Million |
| Debt repayment | - | -65 Thousand | -10 Thousand | -13.92 Million |
| Dividends payments | - | - | - | - |
| Common Stock Repurchased | - | - | - | - |
| Common Stock Issuance | 7.33 Million | 377.77 Million | 69 Million | 114.37 Million |
| Other Financing Activities | 761.15 Thousand | -2.53 Million | - | -103.05 Million |
| Accounts receivables | 3.31 Million | -3.9 Million | -4.6 Million | - |
| Accounts payables | 4.6 Million | -2.02 Million | 8.57 Million | 48.3 Thousand |
| Inventory | -3.31 Million | 5.92 Million | -135.48 Thousand | - |
| Other working capital | 723.32 Thousand | 11.46 Million | -16.97 Thousand | -576.3 Thousand |
| Cash at beginning of period | 425.02 Million | 53.09 Million | 7.86 Million | 2.5 Million |
| Cash at end of period | 309.36 Million | 438.52 Million | 53.09 Million | 7.86 Million |
| Capital Expenditure | -21.8 Thousand | -13 Thousand | -20 Thousand | -13 Thousand |
| Effect of forex changes on cash | 4.59 Million | 1.56 Million | 1.42 Million | 24 Thousand |
| Net cash flow / Change in cash | -115.65 Million | 385.43 Million | 45.23 Million | 5.36 Million |
| Free Cash Flow | -128.34 Million | 7.95 Million | -25.18 Million | -5.98 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -36.34 Million | -87.25 Million | -160.78 Million | -42.53 Million | -46.08 Million | -36.3 Million |
| Depreciation & Amortization | 17.7 Thousand | 13.95 Thousand | 44.52 Thousand | 5171.21 | 6154.97 | 25.62 Thousand |
| Deferred income taxes | - | - | 4.74 Million | - | - | - |
| Stock-based compensation | 7.72 Million | 7.36 Million | 22.32 Million | 5.06 Million | 5.55 Million | 5.09 Million |
| Change in working capital | -13.59 Million | -9.43 Million | 5.33 Million | 2.43 Million | 2.62 Million | 2.56 Million |
| Other non-cash items | 1863.60 | 930.50 | 5452.19 | 2.54 Million | 2.58 Million | -5.15 Million |
| Investing Cash Flow | -194.74 Thousand | -358.24 Thousand | -21.8 Thousand | -2.6 Million | -2.6 Million | 5.15 Million |
| Investments in PPE | -194.74 Thousand | -358.24 Thousand | -21.8 Thousand | -8866.88 | -9348.33 | 2432.53 |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | -21.8 Thousand | -2.59 Million | -2.59 Million | - |
| Financing Cash Flow | 4.34 Million | 184.4 Million | 8.09 Million | 19.86 Thousand | 198.76 Thousand | 5.8 Million |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 4.34 Million | 177.24 Million | 7.33 Million | - | - | 8.02 Million |
| Other Financing Activities | 4.34 Million | -1.39 Million | 761.15 Thousand | 19.86 Thousand | 198.76 Thousand | - |
| Accounts receivables | -8.61 Million | 824.42 Thousand | 3.31 Million | - | - | - |
| Accounts payables | -3.11 Million | -7.73 Million | 4.6 Million | - | - | 3.97 Million |
| Inventory | - | - | -3.31 Million | - | - | - |
| Other working capital | -2.12 Million | -1.3 Million | 723.32 Thousand | 2.43 Million | 2.62 Million | -1.59 Million |
| Cash at beginning of period | 448.33 Million | 316.78 Million | 425.02 Million | - | 381.86 Million | 404.63 Million |
| Cash at end of period | 401.33 Million | 447.7 Million | 309.36 Million | -30.09 Million | 349.21 Million | 382.12 Million |
| Capital Expenditure | -194.74 Thousand | -358.24 Thousand | -21.8 Thousand | -8866.88 | -9348.33 | 2432.53 |
| Effect of forex changes on cash | -847 Thousand | -2.32 Million | 4.59 Million | 4.97 Million | 5.07 Million | -8.14 Million |
| Net cash flow / Change in cash | -46.99 Million | 130.91 Million | -115.65 Million | -30.09 Million | -32.65 Million | -22.51 Million |
| Free Cash Flow | -50.49 Million | -51.16 Million | -128.34 Million | -32.49 Million | -35.33 Million | -33.41 Million |
THRM
FSM
BCSAU
VLVCY
6257
COLUM